Fused bicyclic RAF inhibitors and methods for use thereof

Inventors

BELFIELD, Andrew • Jones, Clifford David • MARGATHE, Jean-François • COLLETTO, Chiara

Assignees

Redx Pharma Ltd • Jazz Pharmaceuticals Ireland Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11858930-B2

Patent

Publication Date

2024-01-02

Expiration Date


Abstract

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

Core Innovation

The invention relates to compounds of formula (I), including pharmaceutically acceptable salts, tautomers, and stereoisomers. Ring A is selected from imidazole, pyrazole, or triazole, and substituent patterns are defined by R1 and R2, where one of R1 or R2 is H and the other is selected from substituted C1-8 alkyl, unsubstituted C5-8 alkyl, substituted or unsubstituted C1-8 haloalkyl, substituted monocyclic aryl, substituted monocyclic heteroaryl, unsubstituted tetrahydropyran, substituted indazole, or substituted benzoimidazole.

An alternative embodiment provides that R1 and R2 together form a 5- or 6-membered saturated, partially unsaturated, or unsaturated ring containing 0, 1, or 2 heteroatoms selected from N, O, or S, with selected substituents including alkyl, alkoxy, halogenated alkyl, cyano, hydroxy, amino, and substituted amino groups. The disclosure includes representative compounds and synthetic exemplification within the scaffold family, including imidazole, pyrazole, benzimidazole, triazole, and related heteroaryl variants, together with UPLC-MS and 1H NMR characterization.

The partial content also describes compounds positioned as RAF inhibitors via pan-RAF inhibition and RAF kinase modulation, including references to BRAF and BRAF V600E. The examples are presented as compound structures and product identities within the claimed formula scope, including the alternative ring-forming R1/R2 embodiments and the imidazole-specific restriction on substituted monocyclic aryl selection.

Claims Coverage

The consolidated claim coverage centers on a compound of formula (I) and pharmaceutically acceptable forms, with ring A limited to imidazole, pyrazole, or triazole and with defined R1/R2 substitution patterns. Across the provided claim text, there are two main inventive features in the independent compound scope, plus a further imidazole-specific restriction; dependent claim language also covers pharmaceutical compositions and cancer treatment methods.

Imidazole, pyrazole, or triazole ring A selection

A compound of formula (I), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein ring A is an imidazole, a pyrazole, or a triazole.

R1 and R2 substituent pattern with alternative ring formation

One of R1 or R2 is a substituted C1-8 alkyl, an unsubstituted C5-8 alkyl, a substituted or unsubstituted C1-8 haloalkyl, a substituted monocyclic aryl, substituted monocyclic heteroaryl, unsubstituted tetrahydropyran, substituted indazole, or substituted benzoimidazole, and the other R1 or R2 is H; alternatively R1 and R2 together with the atoms to which they are attached form a 5- or 6-membered saturated, partially unsaturated, or unsaturated ring containing 0, 1, or 2 heteroatoms selected from N, O, or S, substituted with 1 or 2 substituents selected from the enumerated list.

Imidazole-specific restriction on substituted monocyclic aryl

When ring A is an imidazole, the substituted monocyclic aryl of R1 or R2 is restricted as stated in the claim text.

Pharmaceutical composition with excipient or carrier

A pharmaceutical composition includes the compound together with a pharmaceutically acceptable excipient or carrier, and may include an additional therapeutic agent selected from the stated therapeutic classes.

Treatment of colorectal cancer or melanoma

A method of treating cancer by administering an effective amount of the compound to a subject in need of treatment, where the cancer is colorectal cancer or melanoma.

BRAF V600E mutation context

The cancer to be treated comprises a BRAF V600E mutation.

The claims cover a compound class defined by ring A selection and detailed R1/R2 substitution architecture, including an alternative where R1 and R2 form a heteroatom-containing ring and a further restriction for the imidazole case. The claim set also extends to pharmaceutical compositions and methods of treating colorectal cancer or melanoma, including cancers comprising a BRAF V600E mutation.

Stated Advantages

Documented Applications

Treatment of colorectal cancer and melanoma using the claimed compounds.

Treatment of cancer comprising a BRAF V600E mutation.

Pharmaceutical compositions including the compound together with a pharmaceutically acceptable excipient or carrier, optionally with an additional therapeutic agent.

Assessment of ERK1/2 phosphorylation (pERK1/2 at p-T202/Y204).

3D proliferation assessment using CellTiter-Glo 3D.

Microsomal stability evaluation using liver microsomes.

Plasma protein binding evaluation using equilibrium dialysis.

Solubility assessment using FeSSIF solubility measurements.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.